(Q37768962)

22 August 2017

1 reference

title

Targeted trials in ovarian cancer (English)

1 reference

22 August 2017

1 reference

Jonathan A Ledermann

1

1 reference

PubMed ID

20591473

22 August 2017

Fharat A Raja

series ordinal

2

1 reference

PubMed ID

20591473

22 August 2017

language of work or name

English

0 references

publication date

29 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

119

1 reference

22 August 2017

1

1 reference

22 August 2017

151-156

1 reference

Tumor angiogenesis: therapeutic implications

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

VEGF-targeted therapy: mechanisms of anti-tumour activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Profound but Dysfunctional Lymphangiogenesis via Vascular Endothelial Growth Factor Ligands from CD11b+ Macrophages in Advanced Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Vascular endothelial growth factor in ovarian cyst fluid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Markedly elevated levels of vascular endothelial growth factor in malignant ascites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

VEGF-Trap: a VEGF blocker with potent antitumor effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Genome maintenance mechanisms for preventing cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Hallmarks of 'BRCAness' in sporadic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Targeting the DNA repair defect of BRCA tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Folate receptor alpha as a tumor target in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

Overexpression of folate binding protein in ovarian cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

The insulin-like growth factor-I receptor as a target for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.008

10.1016/J.YGYNO.2010.05.008

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20591473